Skip to main content
SpringerLink
Log in

Lupus Nephritis

  • Chapter
  • First Online:
Book cover Lupus Erythematosus

  • 2008 Accesses

Abstract

Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder characterized by the production of multiple autoantibodies, a striking female predominance, and the frequent development of immune complex-mediated glomerulonephritis.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Sources

  1. Appel GB, Cohen DJ, Pirani CL, et al. Long-term follow-up of patients with lupus nephritis. A study based on the classification of the World Health Organization. Am J Med. 1987;83:877.

    Article  PubMed  CAS  Google Scholar 

  2. Austin 3rd HA, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544.

    Article  PubMed  Google Scholar 

  3. Contreras G, Pardo V, Cely C, et al. Factors associated with poor outcomes in patients with lupus nephritis. Lupus. 2005;14:890.

    Article  PubMed  CAS  Google Scholar 

  4. Schwartz MM, Lan SP, Bernstein J, et al. Role of pathology indices in the management of severe lupus glomerulonephritis. Lupus Nephritis Collaborative Study Group. Kidney Int. 1992;42:743.

    Article  PubMed  CAS  Google Scholar 

  5. Esdaile JM, Joseph L, MacKenzie T, et al. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046.

    PubMed  CAS  Google Scholar 

  6. Faurschou M, Starklint H, Halberg P, Jacobsen S. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol. 2006;33:1563.

    PubMed  Google Scholar 

  7. Korbet SM, Lewis EJ, Schwartz MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis. 2000;35:904.

    Article  PubMed  CAS  Google Scholar 

  8. Chen YE, Korbet SM, Katz RS, et al. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46.

    Article  PubMed  CAS  Google Scholar 

  9. Chan TM, Tse KC, Tang CS, et al. Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus. 2005;14:265.

    Article  PubMed  CAS  Google Scholar 

  10. Korbet SM, Schwartz MM, Evans J, Lewis EJ, Collaborative Study Group. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007;18:244.

    Article  PubMed  Google Scholar 

  11. Illei GG, Takada K, Parkin D, et al. Renal flares are common in patients with severe proliferative lupus nephritis treated with pulse immunosuppressive therapy: long-term followup of a cohort of 145 patients participating in randomized controlled studies. Arthritis Rheum. 2002;46:995.

    Article  PubMed  CAS  Google Scholar 

  12. Moroni G, Quaglini S, Maccario M, et al. “Nephritic flares” are predictors of bad long-term renal outcome in lupus nephritis. Kidney Int. 1996;50:2047.

    Article  PubMed  CAS  Google Scholar 

  13. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997;51:1188.

    Article  PubMed  CAS  Google Scholar 

  14. Alarcón GS, McGwin Jr G, Bastian HM, et al. Systemic lupus erythematosus in three ethnic groups. VII [correction of VIII]. Predictors of early mortality in the LUMINA cohort. LUMINA Study Group. Arthritis Rheum. 2001;45:191.

    Article  PubMed  Google Scholar 

  15. Adler M, Chambers S, Edwards C, et al. An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period. Rheumatology (Oxford). 2006;45:1144.

    Article  CAS  Google Scholar 

  16. Valeri A, Radhakrishnan J, Estes D, et al. Intravenous pulse cyclophosphamide treatment of severe lupus nephritis: a prospective five-year study. Clin Nephrol. 1994;42:71.

    PubMed  CAS  Google Scholar 

  17. Cheigh JS, Kim H, Stenzel KH, et al. Systemic lupus erythematosus in patients with end-stage renal disease: long-term follow-up on the prognosis of patients and the evolution of lupus activity. Am J Kidney Dis. 1990;16:189.

    PubMed  CAS  Google Scholar 

  18. Appel GB, Contreras G, Dooley MA, et al. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20:1103.

    Article  PubMed  CAS  Google Scholar 

  19. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971.

    Article  PubMed  CAS  Google Scholar 

  20. Gourley MF, Austin 3rd HA, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis. A randomized, controlled trial. Ann Intern Med. 1996;125:549.

    PubMed  CAS  Google Scholar 

  21. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248.

    PubMed  CAS  Google Scholar 

  22. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Immunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002;46:2121.

    Article  PubMed  CAS  Google Scholar 

  23. Yee CS, Gordon C, Dostal C, et al. EULAR randomised controlled trial of pulse cyclophosphamide and methylprednisolone versus continuous cyclophosphamide and prednisolone followed by azathioprine and prednisolone in lupus nephritis. Ann Rheum Dis. 2004;63:525.

    Article  PubMed  CAS  Google Scholar 

  24. Houssiau FA, Vasconcelos C, D’Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Arthritis Rheum. 2010;69:61.

    CAS  Google Scholar 

  25. Houssiau FA, Vasconcelos C, D’Cruz D, et al. Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum. 2004;50:3934.

    Article  PubMed  Google Scholar 

  26. Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010;49:128.

    Article  PubMed  Google Scholar 

  27. Kamanamool N, McEvoy M, Attia J, et al. Efficacy and adverse events of mycophenolate mofetil versus cyclophosphamide for induction therapy of lupus nephritis: systematic review and meta-analysis. Medicine (Baltimore). 2010;89:227.

    Article  CAS  Google Scholar 

  28. Chan TM, Tse KC, Tang CS, et al. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005;16:1076.

    Article  PubMed  CAS  Google Scholar 

  29. Lewis EJ, Hunsicker LG, Lan SP, et al. A controlled trial of plasmapheresis therapy in severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. N Engl J Med. 1992;326:1373.

    Article  PubMed  CAS  Google Scholar 

  30. Ioannidis JP, Boki KA, Katsorida ME, et al. Remission, relapse, and re-remission of proliferative lupus nephritis treated with cyclophosphamide. Kidney Int. 2000;57:258.

    Article  PubMed  CAS  Google Scholar 

  31. Mosca M, Bencivelli W, Neri R, et al. Renal flares in 91 SLE patients with diffuse proliferative glomerulonephritis. Kidney Int. 2002;61:1502.

    Article  PubMed  Google Scholar 

  32. Moroni G, Gallelli B, Quaglini S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transplant. 2006;21:1541.

    Article  PubMed  CAS  Google Scholar 

  33. Grootscholten C, Berden JH. Discontinuation of immunosuppression in proliferative lupus nephritis: is it possible? Nephrol Dial Transplant. 2006;21:1465.

    Article  PubMed  Google Scholar 

  34. Renal Disease Subcommittee of the American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria. The American College of rheumatology response criteria for proliferative and membranous renal disease in systemic lupus erythematosus clinical trials. Arthritis Rheum. 2006;54:421–32.

    Article  Google Scholar 

  35. Houssiau FA, D-Cruz D, Sangle S, et al. Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial. Ann Rheum Dis. 2010;69:2083–9.

    Article  PubMed  CAS  Google Scholar 

  36. Falk RJ, Schur PH, Appel GB. Therapy of diffuse or focal proliferative lupus nephritis. In: Basow DS, editor. UpToDate. Waltham: UpToDate; 2011.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology and Immunology, University of North Carolina at Chapel Hill, CB# 7280, 3330 Thurston Building, Chapel Hill, NC, 27599, USA

    Mary Anne Dooley M.D., M.P.H.

Authors
  1. Mary Anne Dooley M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mary Anne Dooley M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Brigham and Women's Hospital, Harvard Medical School, Div. of Rheumatology/Immunology/Allergy, Francis Street 75, Boston, 02115, USA

    Peter H. Schur

  2. Div. of Rheumatology/Immunology/Allergy, Brigham and Women's Hospital, Lupus Center, Francis Street 75, Boston, 02115, Massachusetts, USA

    Elena M. Massarotti

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Dooley, M.A. (2012). Lupus Nephritis. In: Schur, P., Massarotti, E. (eds) Lupus Erythematosus. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-1189-5_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-1189-5_11

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-1188-8

  • Online ISBN: 978-1-4614-1189-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation